Literature DB >> 22482714

Henipavirus outbreaks to antivirals: the current status of potential therapeutics.

Christopher C Broder1.   

Abstract

The henipaviruses, Hendra virus and Nipah virus, are classic examples of recently emerged viral zoonoses. In a relatively short time since their discoveries in the mid and late 1990s, respectively, a great deal of new information has been accumulated detailing their biology and certain unique characteristics. Their broad species tropism and abilities to cause severe and often fatal respiratory and/or neurologic disease in both animals and humans has sparked considerable interest in developing effective antiviral strategies to prevent or treat henipavirus infection and disease. Here, recent findings on the few most advanced henipavirus countermeasures are summarized and discussed. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22482714      PMCID: PMC4347837          DOI: 10.1016/j.coviro.2012.02.016

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  68 in total

1.  Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.

Authors:  Zhongyu Zhu; Antony S Dimitrov; Katharine N Bossart; Gary Crameri; Kimberly A Bishop; Vidita Choudhry; Bruce A Mungall; Yan-Ru Feng; Anil Choudhary; Mei-Yun Zhang; Yang Feng; Lin-Fa Wang; Xiaodong Xiao; Bryan T Eaton; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Protein structure prediction on the Web: a case study using the Phyre server.

Authors:  Lawrence A Kelley; Michael J E Sternberg
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

3.  Equine morbillivirus pneumonia: susceptibility of laboratory animals to the virus.

Authors:  H A Westbury; P T Hooper; P W Selleck; P K Murray
Journal:  Aust Vet J       Date:  1995-07       Impact factor: 1.281

4.  A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge.

Authors:  Jackie Pallister; Deborah Middleton; Lin-Fa Wang; Reuben Klein; Jessica Haining; Rachel Robinson; Manabu Yamada; John White; Jean Payne; Yan-Ru Feng; Yee-Peng Chan; Christopher C Broder
Journal:  Vaccine       Date:  2011-07-01       Impact factor: 3.641

5.  The lesions of experimental equine morbillivirus disease in cats and guinea pigs.

Authors:  P T Hooper; H A Westbury; G M Russell
Journal:  Vet Pathol       Date:  1997-07       Impact factor: 2.221

6.  Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry.

Authors:  Matteo Porotto; Barry Rockx; Christine C Yokoyama; Aparna Talekar; Ilaria Devito; Laura M Palermo; Jie Liu; Riccardo Cortese; Min Lu; Heinz Feldmann; Antonello Pessi; Anne Moscona
Journal:  PLoS Pathog       Date:  2010-10-28       Impact factor: 6.823

7.  A golden hamster model for human acute Nipah virus infection.

Authors:  K Thong Wong; Isabelle Grosjean; Christine Brisson; Barissa Blanquier; Michelle Fevre-Montange; Arlette Bernard; Philippe Loth; Marie-Claude Georges-Courbot; Michelle Chevallier; Hideo Akaoka; Philippe Marianneau; Sai Kit Lam; T Fabian Wild; Vincent Deubel
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

8.  Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2.

Authors:  Thomas A Bowden; A Radu Aricescu; Robert J C Gilbert; Jonathan M Grimes; E Yvonne Jones; David I Stuart
Journal:  Nat Struct Mol Biol       Date:  2008-05-18       Impact factor: 15.369

9.  Identifying Hendra virus diversity in pteropid bats.

Authors:  Ina Smith; Alice Broos; Carol de Jong; Anne Zeddeman; Craig Smith; Greg Smith; Fred Moore; Jennifer Barr; Gary Crameri; Glenn Marsh; Mary Tachedjian; Meng Yu; Yu Hsin Kung; Lin-Fa Wang; Hume Field
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

10.  Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007.

Authors:  Stephen P Luby; M Jahangir Hossain; Emily S Gurley; Be Nazir Ahmed; Shakila Banu; Salah Uddin Khan; Nusrat Homaira; Paul A Rota; Pierre E Rollin; James A Comer; Eben Kenah; Thomas G Ksiazek; Mahmudur Rahman
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

View more
  27 in total

1.  A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.

Authors:  Katharine N Bossart; Barry Rockx; Friederike Feldmann; Doug Brining; Dana Scott; Rachel LaCasse; Joan B Geisbert; Yan-Ru Feng; Yee-Peng Chan; Andrew C Hickey; Christopher C Broder; Heinz Feldmann; Thomas W Geisbert
Journal:  Sci Transl Med       Date:  2012-08-08       Impact factor: 17.956

Review 2.  A treatment for and vaccine against the deadly Hendra and Nipah viruses.

Authors:  Christopher C Broder; Kai Xu; Dimitar B Nikolov; Zhongyu Zhu; Dimiter S Dimitrov; Deborah Middleton; Jackie Pallister; Thomas W Geisbert; Katharine N Bossart; Lin-Fa Wang
Journal:  Antiviral Res       Date:  2013-07-06       Impact factor: 5.970

3.  Hendra virus and Nipah virus animal vaccines.

Authors:  Christopher C Broder; Dawn L Weir; Peter A Reid
Journal:  Vaccine       Date:  2016-05-04       Impact factor: 3.641

4.  Identification of a region in the stalk domain of the nipah virus receptor binding protein that is critical for fusion activation.

Authors:  Aparna Talekar; Ilaria DeVito; Zuhair Salah; Samantha G Palmer; Anasuya Chattopadhyay; John K Rose; Rui Xu; Ian A Wilson; Anne Moscona; Matteo Porotto
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

5.  A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.

Authors:  Chad E Mire; Joan B Geisbert; Krystle N Agans; Yan-Ru Feng; Karla A Fenton; Katharine N Bossart; Lianying Yan; Yee-Peng Chan; Christopher C Broder; Thomas W Geisbert
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

6.  Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody.

Authors:  Thomas W Geisbert; Chad E Mire; Joan B Geisbert; Yee-Peng Chan; Krystle N Agans; Friederike Feldmann; Karla A Fenton; Zhongyu Zhu; Dimiter S Dimitrov; Dana P Scott; Katharine N Bossart; Heinz Feldmann; Christopher C Broder
Journal:  Sci Transl Med       Date:  2014-06-25       Impact factor: 17.956

7.  Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins.

Authors:  Yee-Peng Chan; Min Lu; Somnath Dutta; Lianying Yan; Jennifer Barr; Michael Flora; Yan-Ru Feng; Kai Xu; Dimitar B Nikolov; Lin-Fa Wang; Georgios Skiniotis; Christopher C Broder
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

Review 8.  Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Authors:  Lars Petter Jordheim; David Durantel; Fabien Zoulim; Charles Dumontet
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

9.  Henipavirus W Proteins Interact with 14-3-3 To Modulate Host Gene Expression.

Authors:  Megan R Edwards; Mikayla Hoad; Sofiya Tsimbalyuk; Andrea R Menicucci; Ilhem Messaoudi; Jade K Forwood; Christopher F Basler
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

10.  Crystal structure of the nipah virus phosphoprotein tetramerization domain.

Authors:  Jessica F Bruhn; Katherine C Barnett; Jaclyn Bibby; Jens M H Thomas; Ronan M Keegan; Daniel J Rigden; Zachary A Bornholdt; Erica Ollmann Saphire
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.